SA109300394B1 - ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها - Google Patents

ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها Download PDF

Info

Publication number
SA109300394B1
SA109300394B1 SA109300394A SA109300394A SA109300394B1 SA 109300394 B1 SA109300394 B1 SA 109300394B1 SA 109300394 A SA109300394 A SA 109300394A SA 109300394 A SA109300394 A SA 109300394A SA 109300394 B1 SA109300394 B1 SA 109300394B1
Authority
SA
Saudi Arabia
Prior art keywords
compound
isoquinolin
thiazolo
hydroxy
atoms
Prior art date
Application number
SA109300394A
Other languages
Arabic (ar)
English (en)
Inventor
روبرتو بيليكشياري
فلافيو موروني
Original Assignee
ويث
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ويث filed Critical ويث
Publication of SA109300394B1 publication Critical patent/SA109300394B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SA109300394A 2008-06-19 2009-06-17 ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها SA109300394B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7385708P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
SA109300394B1 true SA109300394B1 (ar) 2013-01-22

Family

ID=41087350

Family Applications (1)

Application Number Title Priority Date Filing Date
SA109300394A SA109300394B1 (ar) 2008-06-19 2009-06-17 ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها

Country Status (12)

Country Link
US (3) US8299090B2 (enExample)
EP (2) EP2303895B1 (enExample)
JP (2) JP5564495B2 (enExample)
AR (1) AR072265A1 (enExample)
AU (1) AU2009260060B2 (enExample)
CA (1) CA2728454C (enExample)
DK (1) DK2303895T3 (enExample)
ES (1) ES2530815T3 (enExample)
HK (1) HK1212698A1 (enExample)
SA (1) SA109300394B1 (enExample)
TW (1) TWI471329B (enExample)
WO (1) WO2009155402A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2009155413A1 (en) * 2008-06-19 2009-12-23 Wyeth Thienyl- and furanyl-isoquinolinones and methods for using them
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005745B1 (en) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
ATE533812T1 (de) 2005-08-01 2011-12-15 Wietek Holding Gmbh Verfahren zur rezyklierung von kunststoff
WO2007149907A2 (en) 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2009155413A1 (en) * 2008-06-19 2009-12-23 Wyeth Thienyl- and furanyl-isoquinolinones and methods for using them

Also Published As

Publication number Publication date
TWI471329B (zh) 2015-02-01
JP2011525185A (ja) 2011-09-15
WO2009155402A1 (en) 2009-12-23
JP5564495B2 (ja) 2014-07-30
TW201002725A (en) 2010-01-16
US8299090B2 (en) 2012-10-30
HK1156310A1 (en) 2012-06-08
JP2014122242A (ja) 2014-07-03
US20130059843A1 (en) 2013-03-07
US20150133443A1 (en) 2015-05-14
AU2009260060A1 (en) 2009-12-23
AR072265A1 (es) 2010-08-18
EP2896626A1 (en) 2015-07-22
CA2728454C (en) 2017-01-17
HK1212698A1 (en) 2016-06-17
EP2303895B1 (en) 2014-09-24
CA2728454A1 (en) 2009-12-23
US20090318442A1 (en) 2009-12-24
AU2009260060B2 (en) 2015-01-22
DK2303895T3 (en) 2015-01-12
US9265769B2 (en) 2016-02-23
EP2303895A1 (en) 2011-04-06
ES2530815T3 (es) 2015-03-05
US8906935B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
SA109300394B1 (ar) ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
US20210188808A1 (en) Compounds as neuronal histamine receptor-3 antagonists and uses thereof
MXPA05010563A (es) Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
US10654867B2 (en) Heteroaryl estrogen receptor modulators and uses thereof
CN115557949A (zh) 四环类衍生物、其制备方法及其在医药上的应用
JP2013530951A (ja) ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物
EP1845970B1 (en) Tumor necrosis factor inhibitors
EP4149629B1 (en) Purine derivatives as sik-3 inhibitors
JP2023522045A (ja) アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用
KR20150021120A (ko) 헤테로아릴 화합물 및 이의 이용 방법
EP4112053A1 (en) Treatment of synucleinopathies
CN111718350B (zh) 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
SA109300406B1 (ar) ثينيل- وفيرانيل أيزوكوينولينونات وطرق لاستخدامها
CN108864114B (zh) 选择性a2a受体拮抗剂
EP3049400A1 (en) New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof
CN120424018A (zh) 5-氨基-1-取代-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用
KR20200085815A (ko) 과증식성 질병의 치료를 위한 카페인산 유도체
HK1156310B (en) Thiazolyl- and oxazolyl-isoquinolinones and methods for using them